To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Sorafenib Improves Overall Survival in Patients With Advanced Liver Cancer URL: http://www.pslgroup.com/dg/226412.htm Doctor's Guide July 23, 2008
NEW YORK -- July 23, 2008 -- Patients with advanced liver cancer who received treatment with sorafenib (Nexavar) lived about 44% longer compared with patients who did not receive the drug, according to a study published in the July 23 issue of the New England Journal of Medicine. "This is the first time that we've had an effective systemic treatment for liver cancer," said lead author Josep Llovet, MD, Mount Sinai School of Medicine, New York, New York, and Barcelona Clinic Liver Cancer Group, Barcelona, Spain. "Our findings demonstrated survival advantages that are both statistically significant and clinically meaningful." Dr. Llovet and colleagues examined overall survival and time to progression among patients with previously untreated liver cancer. The study included 602 patients who were randomly assigned to receive either sorafenib 400 mg BID (n = 299) or a placebo (n = 303). Patients who received sorafenib lived a median of 10.7 months longer compared with 7.9 months for those who received a placebo. Time to cancer progression was also significantly longer in the treatment group (5.5 vs 2.8 months). Due to the positive findings, the study was terminated early. The incidence of adverse effects was similar between the sorafenib group (52%) and the placebo group (54%). The most common moderate to serious side effects were diarrhoea (11% vs 2%), skin reactions in the hands and feet (8% vs 1%), fatigue (10% vs 15%), and bleeding (6% vs 9%). SOURCE: The Mount Sinai Hospital/The Mount Sinai School of Medicine --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.